Moderna Inc. ($MRNA) Stock Forecast: Up 5.1% Today

What is Moderna Inc.?

Moderna Inc. (MRNA) is a biotechnology company known for its innovative mRNA technology, particularly in the development of vaccines. The stock experienced a strong bullish movement today.

Why is Moderna Inc. going up?

MRNA stock is up 5.1% on May 20, 2026 17:05

• Moderna's stock surged by 20% due to emerging hantavirus cases, showcasing the market's confidence in the company's pandemic defense capabilities.
• The hantavirus scare not only boosted Moderna's stock but also highlighted the potential changes in vaccine-related regulatory environments, which could further benefit the company.
• Despite concerns about declining sales and profitability, Moderna's focus on infectious disease platforms and potential vaccine developments seems to have overshadowed these worries, driving the bullish movement in its stock today.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform

Moderna's stock saw a 20% surge due to emerging hantavirus cases, reminding investors of its pandemic defense capabilities, despite experts suggesting the virus poses a low global risk. While the company has early-stage hantavirus vaccine projects, its broader infectious disease pipeline has been reduced due to shifting U.S. government support and a focus on profitability. The hantavirus scare nonetheless provides an opportunity for Moderna to build goodwill and highlights the potential for changes in vaccine-related regulatory environments.

https://www.biospace.com/business/modernas-stock-rides-hantavirus-fears-as-spotlight-returns-to-infectious-disease-platform

ROIV: Strong clinical progress and a $2.25B Moderna settlement drive robust financial position

Roivant Sciences (ROIV) has demonstrated strong clinical progress with IMVT-1402 and brepocitinib, the latter receiving FDA Breakthrough Therapy Designation. Furthermore, a substantial $2.25 billion settlement with Moderna has significantly bolstered the company's financial standing, bringing its cash and securities to $4.3 billion. This combination of clinical advancements and a strong financial position paints a robust outlook for ROIV.

https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3350866:0-roiv-strong-clinical-progress-and-a-2-25b-moderna-settlement-drive-robust-financial-position/

Harvest Portfolios Group Inc. Has $63.10 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Harvest Portfolios Group Inc. reduced its stake in Regeneron Pharmaceuticals (REGN) by 24% in Q4, now holding 81,748 shares valued at approximately $63.1 million. Despite this reduction, Wall Street analysts maintain a "Moderate Buy" consensus for REGN with an average price target of $792.65. Regeneron Pharmaceuticals recently beat earnings expectations with $9.47 EPS and $3.61 billion in revenue, and declared a quarterly dividend of $0.94 per share.

https://www.marketbeat.com/instant-alerts/filing-harvest-portfolios-group-inc-has-6310-million-stock-holdings-in-regeneron-pharmaceuticals-inc-regn-2026-05-20/

Moderna Inc. stock (US60770K1034): FDA path, vaccine sales and pipeline updates in focus

Moderna Inc. (US60770K1034) shares are closely watched by U.S. investors due to developments in its mRNA pipeline, vaccine demand, and regulatory milestones. The company's stock is highly sensitive to trial results, FDA decisions, and commercial guidance, as it seeks to diversify revenue beyond COVID-19 products. Success in its respiratory, cancer, and rare disease programs will be key to transitioning from a single-product revenue model to a more stable growth story.

https://www.ad-hoc-news.de/boerse/news/ueberblick/moderna-inc-stock-us60770k1034-fda-path-vaccine-sales-and-pipeline/69379731

2 Healthcare Stocks Worth Investigating and 1 Facing Headwinds

This article analyzes three healthcare stocks, recommending two for investigation and one to potentially avoid. Moderna is highlighted as a stock to sell due to declining sales, profitability, and free cash flow margin. Conversely, Intuitive Surgical is presented as a strong watch due to robust revenue growth, share buybacks, and a healthy free cash flow margin, while BrightSpring Health Services is also recommended for its impressive revenue growth, large revenue base, and strong future growth estimates.

https://www.theglobeandmail.com/investing/markets/stocks/MRNA/pressreleases/2032064/2-healthcare-stocks-worth-investigating-and-1-facing-headwinds/

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Upwork Inc. ($UPWK) Stock Forecast: Up 5.3% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Up 5.5% Today

D.R. Horton Inc. ($DHI) Stock Forecast: Up 5.1% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.5% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Up 5.9% Today

CleanSpark Inc ($CLSK) Stock Forecast: Up 7.5% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Up 5.0% Today

Etsy Inc. ($ETSY) Stock Forecast: Up 5.9% Today

Moderna Inc. Price History

12.04.2026 - MRNA Stock was down 6.7%

• Moderna (MRNA) faced a downturn today, potentially influenced by profit-taking following recent positive developments.
• The dip in Merck's stock value, attributed to a one-time charge stemming from an acquisition and a setback in its pipeline, may have impacted overall sentiments towards biotech equities, including Moderna.
• Investor attention could have shifted towards companies like Halozyme Therapeutics (HALO) with optimistic revenue projections, prompting a brief sell-off in Moderna shares.
• Market influencers within the biotech domain embracing cutting-edge technologies such as AI might have diverted focus away from Moderna, contributing to its bearish performance today.

08.04.2026 - MRNA Stock was up 12.8%

• Following the release of positive Phase 3 flu vaccine data, Moderna's stock showed a strong bullish trend. The data highlighted the efficacy of mRNA-1010 compared to standard flu vaccines in older adults.
• Moderna's stock rebounded after favorable earnings and a successful performance in 2026. This reflected investor confidence in the company's mRNA platform and its potential for revenue growth beyond the realm of COVID-19 vaccines.
• The positive Phase 1 data announcement for Moderna's mRNA hantavirus vaccine further boosted investor confidence. This demonstrated how Moderna's mRNA technology can effectively target different viral diseases.
• Moderna's recent bullish market movement can be linked to its successful vaccine developments, robust earnings, and the confirmation of its mRNA platform's potential to address a broad array of health issues.

08.04.2026 - MRNA Stock was up 13.7%

• Moderna's bullish movement can be attributed to the positive Phase 3 flu vaccine data for its mRNA-1010 candidate, showcasing superior efficacy compared to standard flu vaccines.
• The SEC filing indicating a proposed sale of securities might have initially caused some uncertainty but was overshadowed by the promising vaccine results.
• The positive news from Regeneron Pharmaceuticals receiving FDA approval for the first neurosensory gene therapy could have boosted overall investor sentiment in the biotech sector, benefiting Moderna as well.
• Moderna's potential for building durable revenue beyond COVID-19 vaccines with upcoming FDA approvals could have further fueled investor optimism, driving the stock's bullish momentum.

08.04.2026 - MRNA Stock was up 11.8%

• Ongoing research into hantavirus vaccines by Moderna may have boosted investor confidence in the company's ability to address emerging infectious diseases, contributing to the bullish movement.
• A SEC filing indicating a proposed sale of securities by Moderna may have initially caused some uncertainty among investors, but the overall positive sentiment surrounding the company's vaccine development efforts likely overshadowed this news.
• The broader positive sentiment in the biotechnology sector, as evidenced by Cboe Global Markets hitting an all-time high, could have also positively influenced Moderna's stock performance today.
• Moderna's focus on advancing its vaccine pipeline, as seen in the update on its RSV and H5 flu vaccine trial, may have further reinforced investor optimism in the company's long-term growth prospects, contributing to the bullish market movement.

11.04.2026 - MRNA Stock was down 7.7%

• Despite a 6% surge earlier, Moderna's stock faced a bearish movement, potentially influenced by profit-taking following recent positive momentum.
• Initially boosted by renewed interest in Moderna's Hantavirus vaccine due to an outbreak, concerns about normalizing COVID-era revenue and GAAP losses may have contributed to the downturn.
• Investors seem to exercise caution due to uncertainties surrounding the revenue potential of the broader mRNA platform and the company's ability to sustain competitiveness against peers like Pfizer and Novavax in the vaccine sector.
• While the market sentiment towards Moderna remains positive, driven by upcoming Phase 3 readouts and a diverse pipeline, short-term volatility could linger as investors navigate challenges tied to the pandemic.

11.04.2026 - MRNA Stock was down 5.1%

• Moderna's stock increased by 6% today, surpassing other vaccine companies like Pfizer and Novavax. This was driven by heightened interest in its Hantavirus vaccine after a recent outbreak on a cruise ship and robust Q1 2026 revenue results. However, concerns about returning to pre-COVID revenue levels and ongoing losses might have led to profit-taking and a bearish trend in the stock.
• Moderna's wide-ranging mRNA platform, along with upcoming Phase 3 study outcomes, continues to support its positive market momentum despite the recent decline.
• The overall market sentiment towards biotech companies and uncertainties about future revenue sustainability post-COVID may have played a role in today's downward movement for Moderna's stock.
• Investors are likely approaching Moderna's stock with caution due to uncertainties surrounding its revenue sources and future profitability.

20.04.2026 - MRNA Stock was up 5.1%

• Moderna's stock surged by 20% due to emerging hantavirus cases, showcasing the market's confidence in the company's pandemic defense capabilities.
• The hantavirus scare not only boosted Moderna's stock but also highlighted the potential changes in vaccine-related regulatory environments, which could further benefit the company.
• Despite concerns about declining sales and profitability, Moderna's focus on infectious disease platforms and potential vaccine developments seems to have overshadowed these worries, driving the bullish movement in its stock today.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna's stock experienced a bearish movement despite being ranked #1 on a list of Most Impactful Companies, showcasing its significant contributions to mRNA technology and public health.
• The company's Q1 earnings report with an EPS of ($3.40) may have contributed to the drop in share price, signaling potential investor concerns about profitability.
• Investors viewing Moderna as a pandemic hedge amidst reduced demand for Covid vaccines and regulatory challenges might have led to conflicting sentiments and added to the stock's volatility.
• The overall market sentiment towards biotech companies and vaccine manufacturers could have influenced Moderna's stock movement, with investors closely monitoring developments in the healthcare sector.

13.04.2026 - MRNA Stock was down 5.4%

• Moderna observed a downward trend in its stock price today despite investor confidence in its pandemic-related value. Possible reasons for this decline include:
• Decreased demand for Covid vaccines and regulatory challenges impacting investor optimism.
• Moderna faces uncertainties regarding its future trajectory and the viability of potential trading strategies related to the "hantavirus."
• News of Dominari Holdings' strong Q1 revenue growth and Sinovac Foundation's vaccine donations might have shifted investor focus away from Moderna, affecting its stock performance.
• Denison Mines' underwhelming earnings results and a poor financial health rating from InvestingPro could have contributed to negative overall market sentiment in the healthcare and biotech sectors, influencing Moderna's stock performance.

13.04.2026 - MRNA Stock was down 5.4%

• The stock of Moderna faced a downturn despite being acknowledged as a highly impactful company globally.
• Factors such as declining demand for COVID vaccines and a complex regulatory environment may have influenced the market's pessimistic view.
• Investors appear wary of Moderna's future trajectory, particularly as the company navigates critical decisions and places bets on a "hantavirus trade" to regain momentum.
• While Moderna has received acclaim for its mRNA technology innovations, current market sentiment seems more concerned with the company's present obstacles and uncertainties.

19.04.2026 - MRNA Stock was down 5.1%

• Moderna's bearish movement today may be linked to an insider sale by President Stephen Hoge, potentially unsettling investors and adding to stock volatility.
• The market sentiment around mRNA technology and the company's need to stabilize revenue post-pandemic could be contributing to the downward trend, despite positive growth from international partnerships and new vaccines.
• Investors may also be reacting to potential legal risks from intellectual property disputes, as mentioned in a recent conference audio transcript, which might be impacting Moderna's stock performance.
• The company's strong clinical and regulatory progress, beneficial for its long-term prospects, may not be sufficient to counter the immediate market factors influencing today's bearish movement.

19.04.2026 - MRNA Stock was down 6.9%

• Moderna's stock faced a downward trend subsequent to an insider selling 53,336 shares, conducted by President Stephen Hoge. This transaction heightened stock volatility, indicating investor sensitivity to internal activities.
• The market's adverse response to the insider sale potentially reflects uncertainties about Moderna's future growth trajectory and stability post-pandemic.
• Investor focus remains on Moderna's vaccine demand, progress in pipeline projects, and endeavors to stabilize revenue, all pivotal in determining stock performance.
• Noteworthy advancements from Wave Life Sciences regarding its AATD trial possibly impacted the biotech sector positively, while Moderna's descent was influenced by the insider transaction.